A phase 3 safety and efficacy study of boceprevir in combination with peginterferon alfa-2a and ribavirin in subjects with chronic hepatitis C genotype 1 who failed prior treatment with peginterferon/ribaviri
- Conditions
- Chronic Hepatitis CMedDRA version: 9.1Level: LLTClassification code 10008912Term: Chronic hepatitis CMedDRA version: 9.1Level: PTClassification code 10019744Term: Hepatitis CMedDRA version: 9.1Level: SOCClassification code 10021881Term: Infections and infestationsMedDRA version: 9.1Level: SOCClassification code 10019805Term: Hepatobiliary disorders
- Registration Number
- EUCTR2008-004760-39-BE
- Lead Sponsor
- Schering Plough Research Institute, a Division of Schering Corporation
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 198
1. For inclusion in the study, subjects must have a qualifying regimen defined as PEG2a/ribavirin or peginterferon alfa-2b (PEG2b)/ribavirin for a minimum of 12 weeks. If a subject has received more than one such regimen, the most recent regimen is considered the qualifying regimen
Note: Maintenance therapy, following failure of qualifying therapy, with any interferon alfa is acceptable; however, the subject must have discontinued the maintenance therapy at least 1 month prior to the Screening Visit
2. During the qualifying regimen, subjects must have either:
a. A documented undetectable HCV-RNA within 30 days of EOT and a subsequent detectable HCV-RNA during follow-up OR
b. A documented decline in HCV-RNA by >/= 2 log10 by TW 12.
Note: For subjects who did not participate in Schering-Plough Research Institute (SPRI) protocols, qualifying virology reports and documentation of qualifying previous treatment regimen must be completely de-identified and faxed to the sponsor's project physician for confirmation that the subject qualifies for this study
3. Subject must have previously documented CHC genotype 1 infection. Subjects with other or mixed genotypes are not eligible. The HCV-RNA result obtained from the central laboratory at the Screening Visit must confirm genotype 1 infection and be equal or greater than 10,000 IU/mL
4. Subject must have a liver biopsy with histology consistent with CHC and no other etiology. Copies of the pathology report and slides are required for the subject to be included in the study. The study site must be able to access the pathology report and histology slides prior to subject randomization. Two unstained slides are preferred; however, one slide stained with hematoxylin plus eosin (H & E) plus one slide stained with Masson’s trichrome will be accepted (slides should be reviewed by the investigator to confirm adequacy). The central pathologist’s reading will be used for analysis purposes
a. No cirrhosis: Biopsy must be within 3 years of the Screening Visit
b. Cirrhosis: Any historic liver biopsy demonstrating cirrhosis will be accepted regardless of length of time since biopsy
c. Subjects whose timing of liver biopsy does not meet this criterion for subject eligibility may have a liver biopsy performed between Screening and Day 1, if their Screening Visit confirms that the subject meets the other study inclusion criteria
5. Subjects with bridging fibrosis or cirrhosis must have an ultrasound within 6 months of the Screening Visit (or between Screening and Day 1) with no findings suspicious for hepatocellular carcinoma (HCC)
6. Subjects participating in SPRI maintenance protocols P02570 or P02569 must have completed the study (ie, finished last contact) to be eligible for this protocol
7. Subject must be >/=18 years of age
8. Subject must weigh between 40 kg and 125 kg
9. Subject and subject’s partner(s) must each agree to use acceptable methods of contraception for at least 2 weeks prior to Day 1 and continue until at least 6 months after last dose of study drug, or longer if dictated by local regulations
10. Subjects must be willing to give written informed consent
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
1. Subjects known to be coinfected w/HIV or HBV
2. Subjects requiring discontinuation of previous interferon or ribavirin regimen for an AE considered to be possibly/probably related to ribavirin &/or interferon
3. Treatment w/ribavirin w/in 90 days & any interferon alfa w/in 1 month of Screening
4. Treatment for hepatitis C w/any investigational drug. Prior treatment with herbal remedies w/known hepatotoxicity
5. Treatment w/any investigational drug w/in 30 days of the randomization
6. Participation in any other clinical trial w/in 30 days of randomization
7. Evidence of decompensated liver disease including history or presence of clinical ascites, bleeding varices, or hepatic encephalopathy
8. Diabetic &/or hypertensive subjects w/clinically significant ocular findings
9. Pre-existing psychiatric condition(s), including but not limited to:
a. Current moderate or severe depression (mild depression may be enrolled)
b. History of depression associated with: Hospitalization; Electroconvulsive therapy; prolonged absence from work &/or significant disruption of daily functions
c. Suicidal or homicidal ideation &/or attempt
d. History of severe psychiatric disorders
e. Past/current use of lithium
f. Past/current use of antipsychotic drugs
10. Clinical diagnosis of substance abuse of the following drugs w/in the following timeframes:
a. Alcohol, intravenous drugs, inhalational (not including marijuana), psychotropics, narcotics, cocain, prescription or over-the-counter drugs: w/in 1 year of the Screening Visit, OR
b. Multi-drug abuse w/in 3 years of Screening Visit OR
c. Subjects receiving opiate agonist substitution therapy w/in 1 year of Screening (except for subjects monitored in an opioid substitution maintenance program) OR
d. Historic marijuana use is deemed excessive by a physician, or is interfering with the subject's life
11. Any known pre-existing medical condition that could interfere w/the participation in & completion of study, including but not limited to:
a. Central nervous system trauma
b. Current or history of seizure disorder unless >10 years ago, a single isolated event, no anti-seizure medications prescribed, & a normal neurological examination documented in study files w/in 6 months of Day 1
c. History of stroke/transient ischemic attack
d. Immunologically mediated disease
e. Chronic pulmonary disease
f. Current or history of any clinically significant cardiac abnormalities/dysfunction including current uncontrolled hypertension or history of antianginal agents for cardiac conditions
g. Any medical condition requiring chronic systemic administration of corticosteroids during study
h. Active clinical gout w/in 1 year
i. Hemoglobinopathy
j. Myelodysplastic syndromes
k. Coagulopathy
l. Organ transplants other than corneal & hair
m. Poor venous access precluding routine peripheral blood sampling
n. Subjects w/indwelling venous catheters
o. Subjects w/a history of gastric surgery or malabsorption disorders
12. Evidence of active or suspected malignancy or a history of malignancy w/in the last 5 years. Subjects under evaluation for malignancy are not eligible
13. Subjects who are pregnant, nursing or intend to become pregnant during study. Male subjects w/partners who are or intend to become pregnant during study
14. Other conditions making the subject unsuitable for enrollment or could interfere w/the subject participating in & completing study
15. Subjects who are part of the site personnel directly involved with stud
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method